Cargando…
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
BACKGROUND: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Da...
Autores principales: | Sahoo, Abhay Kumar, Das, Sambit, Prusty, Pitambar, Shankar, Anand, Guha, Shaibal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872899/ https://www.ncbi.nlm.nih.gov/pubmed/24404491 http://dx.doi.org/10.4103/2230-8210.122096 |
Ejemplares similares
-
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
por: Sanyal, Debmalya, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A(1)chieve study
por: Joshi, Akhil, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A(1)chieve study
por: Abubaker, Mohammed, et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West India cohort of the A(1)chieve study
por: Jain, Sunil M., et al.
Publicado: (2013) -
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A(1)chieve study
por: Kumar, Surender, et al.
Publicado: (2013)